Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 8/20 | 0.43 |
| ▸ | BRAF | P15056 | 5/20 | 0.43 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | CDK8 | P49336 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | ARAF | P10398 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9105108 | 0.85 | BRAF (0.44) | PPARGPPARARAF1BRAFPLA2G7 | |
| Trifluoroacetic Acid SCHEMBL9105100 | 0.80 | PPARG (0.47) | PPARGPPARARAF1BRAFPLA2G7 | |
| SCHEMBL15428908 | 0.79 | BRAF (0.43) | PPARGPPARARAF1BRAFHDAC1 | |
| SCHEMBL9108277 | 0.78 | SLC6A4 (0.50) | PPARGPPARARAF1BRAFPLA2G7 | |
| SCHEMBL29642151 | 0.78 | SLC6A4 (0.50) | PPARGPPARARAF1BRAFPLA2G7 | |
| SCHEMBL9104205 | 0.78 | IDO1 (0.45) | PPARGPPARARAF1BRAFPLA2G7 | |
| SCHEMBL9900968 | 0.77 | IDO1 (0.48) | PPARGPPARARAF1BRAFPLA2G7 | |
| Trifluoroacetic Acid SCHEMBL9109627 | 0.77 | PPARG (0.53) | PPARGPPARARAF1BRAFPLA2G7 | |
| SCHEMBL29918384 | 0.76 | IDO1 (0.50) | PPARGPPARARAF1BRAFPLA2G7 | |
| SCHEMBL875664 | 0.76 | IDO1 (0.50) | PPARGPPARARAF1BRAFPLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649053-B1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LTD (GB) | 2015-11-04 | — | — | EP | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20140113922-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-04-24 | — | — | US | disclosed |
| US-8637536-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-01-28 | — | — | US | disclosed |
| US-20130252963-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20120142717-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113922-A1 | COMPOUNDS | LIPG, PLA2G1B, ENPP2 | PPARG 679/4885PPARA 484/4885RAF1 2219/4885 |
| US-20120142717-A1 | COMPOUNDS | LIPG, PLA2G1B, ENPP2 | PPARG 679/4885PPARA 484/4885RAF1 2219/4885 |
| US-20130252963-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | PPARG 585/4885PPARA 293/4885RAF1 2941/4885 |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | PPARG 494/4885PPARA 275/4885RAF1 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.